Corcept Therapeutics Incorporated (CORT)

NASDAQ: CORT · Real-Time Price · USD

114.49

-3.83 (-3.24%)

At close: Jul 31, 2026, 4:00 PM EDT

116.76

+2.27 (1.98%)

After-hours: Jul 31, 2026, 7:54 PM EDT

Corcept Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	55.18	99.65	141.21	106.14	101.42	112.51
Depreciation & Amortization	2.04	1.15	0.8	1.04	1.26	1.48
Stock-Based Compensation	96.11	84.5	61.35	48.94	42.44	42.93
Other Adjustments	-19.94	-41.9	-50.59	-37.3	-30.34	11.43
Change in Receivables	-12.35	-5.81	-12.85	-10.07	-3.43	-1.43
Changes in Inventories	-11	-7.48	0.31	1.27	1.2	3.44
Changes in Accounts Payable	-8.97	25.07	-2.02	5.42	4.76	-3.6
Changes in Accrued Expenses	21.44	4.01	50.78	24.41	5.06	5.22
Changes in Income Taxes Payable	-	1.09	3.78	1.21	8.69	0.01
Changes in Other Operating Activities	-15.35	-18.29	5.54	-14.38	-10.73	-4.11
Operating Cash Flow	109.7	142	198.3	126.68	120.32	167.89
Operating Cash Flow Growth	-39.86%	-28.39%	56.53%	5.28%	-28.33%	10.48%

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Capital Expenditures	-2.78	-0.21	-2.17	-0.14	-0.41	-0.47
Purchases of Investments	-322.47	-319.61	-588.31	-328.75	-355.07	-312.81
Proceeds from Sale of Investments	303.35	389.58	412.88	419.79	241.15	449.4
Investing Cash Flow	-21.9	69.76	-177.6	90.91	-114.33	136.13

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Issuance of Common Stock	25.47	25.49	9.62	5.81	4.38	16.23
Repurchase of Common Stock	-104.37	-245.86	-37.97	-154.53	-21.67	-318.82
Net Common Stock Issued (Repurchased)	-78.91	-220.37	-28.35	-148.72	-17.28	-302.59
Financing Cash Flow	-78.91	-220.37	-28.35	-148.72	-17.28	-302.59

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Foreign Exchange Rate Adjustments	-0.6	1.44	-0.23	0.36	-	-
Net Cash Flow	8.29	-7.17	-7.89	69.22	-11.29	1.43

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Free Cash Flow	106.92	141.79	196.12	126.54	119.91	167.42
Free Cash Flow Growth	-40.76%	-27.71%	54.99%	5.53%	-28.38%	11.07%
FCF Margin	12.87%	18.62%	29.05%	26.23%	29.84%	45.75%
Free Cash Flow Per Share	0.93	1.18	1.73	1.13	1.03	1.33
Levered Free Cash Flow	39.59	103.51	196.73	124.33	111.11	114.49
Unlevered Free Cash Flow	-1.2	72.51	176.75	110.25	108.13	114.01

SEC Filings: 10-K · 10-Q